Giant cell arteritis is a systemic vasculitis and careful ... In a 2001 meta-analysis that included 941 biopsy proven cases of GCA, 4% of those with positive biopsies had "normal" ESRs.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first such approval in the disease since tocilizumab received the green light in ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

Rinvoq is a Key Top-Line Driver for AbbVie Rinvoq is a key top-line driver for AbbVie. The drug generated sales of almost $6 billion in 2024, which was up 50.4% year over year, owing to continuous ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.